Kura Oncology (KURA) to Release Quarterly Earnings on Wednesday

Kura Oncology (NASDAQ:KURA) is anticipated to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Kura Oncology Price Performance

Kura Oncology stock opened at $8.48 on Wednesday. The company has a market cap of $737.93 million, a P/E ratio of -3.42 and a beta of 0.23. Kura Oncology has a one year low of $5.41 and a one year high of $12.49. The business has a fifty day moving average of $9.27 and a two-hundred day moving average of $9.23. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 8,180 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $69,202.80. Following the completion of the sale, the insider owned 267,274 shares in the company, valued at $2,261,138.04. This represents a 2.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian T. Powl sold 6,414 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $54,262.44. Following the completion of the transaction, the insider owned 183,275 shares in the company, valued at $1,550,506.50. This trade represents a 3.38% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 59,794 shares of company stock valued at $537,176. 6.40% of the stock is currently owned by insiders.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its position in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after purchasing an additional 9,958 shares in the last quarter. Brevan Howard Capital Management LP acquired a new position in shares of Kura Oncology during the second quarter valued at $80,000. Jain Global LLC acquired a new stake in Kura Oncology in the third quarter worth about $91,000. Lazard Asset Management LLC raised its holdings in Kura Oncology by 222.3% during the 3rd quarter. Lazard Asset Management LLC now owns 10,423 shares of the company’s stock worth $92,000 after purchasing an additional 7,189 shares during the last quarter. Finally, LPL Financial LLC acquired a new position in Kura Oncology during the 4th quarter valued at about $105,000.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on KURA shares. Zacks Research downgraded shares of Kura Oncology from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 20th. Wall Street Zen lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Tuesday, January 13th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Finally, UBS Group raised their price objective on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $28.00.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.